FEATURED ARTICLES

A New Immunotherapy Paradigm: It’s Not Just For Cancer Anymore
A New Immunotherapy Paradigm: It’s Not Just For Cancer Anymore

When Bruce Gillis, CEO of EpicGenetics, decided to look into fibromyalgia, he drew blood from 17 patients and analyzed 35 different immune system factors. When compared to a control group, he was astounded by the results. There was a huge disparity between the immune system markers for the 17 patients and those of the control group. That launched his quest for a cure.

  • Science Driving Gene Therapy Development At bluebird bio
    Science Driving Gene Therapy Development At bluebird bio

    For patients with sickle cell anemia, just getting through the day can be a struggle. Symptoms of the disease include vision problems, swelling of the hands and feet, and periodic episodes of pain that can last from a few hours to a few weeks. In this article Nick Leschly, CEO at bluebird bio, discusses the progress being made with its investigational gene therapy for sickle cell disease.

  • What Is Real-World Evidence, Anyway? Industry Experts Weigh In
    What Is Real-World Evidence, Anyway? Industry Experts Weigh In

    This is the first article in a two-part roundtable Q&A on real-world evidence (RWE) in the 21st century. In this first installment, we will explore common misconceptions surrounding real-world evidence (RWE), what should be considered to achieve good real-world data (RWD) analyses, and the impact this data can have on clinical treatment and regulatory development.

  • How Novartis Developed An Agile Approach To Rapid Study Startup
    How Novartis Developed An Agile Approach To Rapid Study Startup

    Over the last four years, the U.S. Medical Operations group of Novartis Oncology — in collaboration with internal clinical partners — has been transforming the study startup process for Novartis-sponsored studies.

More Featured Articles

WHITE PAPERS & CASE STUDIES

More White Papers & Case Studies

SERVICES & PRODUCTS

DIA NOW DIA NOW

DIA NOW enables on-demand, curated access to actionable insights across DIA's global platforms.

Vaccine Development Services Vaccine Development Services

With emerging and re-emerging infectious diseases the development of new anti-infectives and vaccines presents many challenges. We understand these challenges and our scientific experts can provide you with the strategic guidance to develop and validate custom assays and provide you with the high-quality laboratory services you need to ensure regulatory success.

Bioanalytical & ADME Laboratory Services Bioanalytical & ADME Laboratory Services

Tailored solutions for your most complex challenges
As increasing regulatory and scientific complexities threaten R&D productivity, you need a partner with scientific competence, regulatory expertise and capacity to meet demanding timelines via tailored solutions.

Central Laboratories Central Laboratories

Deeper science to drive tailored solutions, optimized quality systems, delivery excellence and better insights.

Genomic Laboratory Services Genomic Laboratory Services

Access leading-edge technologies, scientific experts and Genomics Know-How®. Q2 Solutions | EA Genomics, advances science from understanding the human genome and disease biology to detecting the effects of therapies.

Medical Writing and Publishing Medical Writing and Publishing

Medical and regulatory documentation developed by experienced medical writing teams plays a pivotal role in the success of a clinical research project.

More Services & Products

NEWS

More News